Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 7Ovarian Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Penile Neoplasms 1Pelvic Neoplasms 1Metastatic Solid Tumors 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colonic Neoplasms 1Advanced Solid Tumors 1

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Platinum 1Nivolumab 1Ipilimumab 1Iodine-125 1Gemcitabine 1FANG vaccine 1Electrocardiography 1Echocardiography 1DOXO-EMCH 1Cetuximab 1Cell- and Tissue-Based Therapy 1Antibodies, Bispecific 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Platinum × Other solid neoplasm × Clear all
NCT07272590 2025-12-09

Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
290 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡